Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICV Administration of CD19-CAR T Cells in CNS Lymphoma
NCT05625594Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2023
- Primary completion
- May 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JCAR014 in central nervous system lymphoma, sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 15 years and Disease response up to 15 years. Started Jun 2023; status: recruiting.
02
Drugs
JCAR014
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT05625594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625594.